TrialJournal of Crohn's & colitis2026

Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.

Britta Siegmund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.